Apnimed Inc(APMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:00 PM ET (Korea 10/23 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 24.95% | Shs Outstand | 41.6M | Perf Week | 1.56% |
| Market Cap | 0.77B | Forward P/E | - | EPS next Y | - | Insider Trans | 3.23% | Shs Float | 31.3M | Perf Month | -17.61% |
| Enterprise Value | 0.92B | PEG | - | EPS next Q | -0.64 | Inst Own | 34.98% | Short Float | 5.65% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 27.34% | Short Ratio | 3.39 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 1.76M | Perf YTD | -15.77% |
| Book/sh | -4.23 | P/C | 4.46 | EPS past 3/5Y | -69.75% - | ROE | - | 52W High | -47.49% ($35.29) | Perf Year | - |
| Cash/sh | 4.15 | P/FCF | - | Sales past 3/5Y | 237.57% - | ROIC | - | 52W Low | 14.95% ($16.12) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 9.19% 10.5% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.06 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 41.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.06 | Sales Q/Q | - | SMA20 | -4.98% ($19.5) | Beta | - | Target Price | $50.33 |
| Payout | - | Debt/Eq | 1.15 | Earnings | 2026/9/8 | SMA50 | -24.17% ($24.44) | Rel Volume | 0.37 | Prev Close | $18.9 |
| Employees | - | LT Debt/Eq | 1.15 | EPS/Sales Surpr. | 905.42% - | SMA200 | -25.03% ($24.72) | Avg Volume(3M) | 0.52M | Price | $18.53 |
| IPO | 2026/7/31 | Option/Short | No/Yes | Trades | 2819 | Volume | 194,817 | Change | -1.96% |
This is a U.S. biotech company developing an oral (pill-based) treatment targeting obstructive sleep apnea. Founded in 2017, it is researching small-molecule drug candidates that act on the neurobiological pathways regulating breathing during sleep, attempting a pharmaceutical approach in a sleep apnea treatment market that has historically been centered on device-based solutions.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded less than usual. That is 37% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.0%.
Tap to view numbers
It ranks #175 of 594 in the industry
Based on market cap of $771M.
FAQ
What kind of company is APMD?
APMD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APMD?
The market cap of APMD is approximately $771M, ranking 2,781 within its sector.
What is the 52-week high and low for APMD?
APMD has recorded a 52-week high of $35.29 and a low of $16.12.
